Combined anticoagulation and antiplatelet therapy for high-risk patients with atrial fibrillation: a systematic review

Research output: Contribution to journalArticle

Standard

Harvard

APA

Vancouver

Author

Bibtex

@article{a326203077674dec9e331502c68538f6,
title = "Combined anticoagulation and antiplatelet therapy for high-risk patients with atrial fibrillation: a systematic review",
abstract = "Previous research suggests uncertainty whether or not there is any additional benefit in adding antiplatelet therapy (APT) to anticoagulation therapy (ACT) in patients with high-risk atrial fibrillation (AF) in terms of reduction in vascular events, including stroke. The existing guidelines acknowledge an increased risk of bleeding associated with such a strategy; however, there is no consensus on the treatment pathway.",
author = "DA Lane and S Raichand and D Moore and M Connock and A Fry-Smith and DA Fitzmaurice",
year = "2013",
month = jul
doi = "10.3310/hta17300",
language = "English",
volume = "17",
pages = "1--188",
journal = "Health Technology Assessment",
issn = "1366-5278",
publisher = "NIHR Health Technology Assessment Programme",
number = "30",

}

RIS

TY - JOUR

T1 - Combined anticoagulation and antiplatelet therapy for high-risk patients with atrial fibrillation

T2 - a systematic review

AU - Lane, DA

AU - Raichand, S

AU - Moore, D

AU - Connock, M

AU - Fry-Smith, A

AU - Fitzmaurice, DA

PY - 2013/7

Y1 - 2013/7

N2 - Previous research suggests uncertainty whether or not there is any additional benefit in adding antiplatelet therapy (APT) to anticoagulation therapy (ACT) in patients with high-risk atrial fibrillation (AF) in terms of reduction in vascular events, including stroke. The existing guidelines acknowledge an increased risk of bleeding associated with such a strategy; however, there is no consensus on the treatment pathway.

AB - Previous research suggests uncertainty whether or not there is any additional benefit in adding antiplatelet therapy (APT) to anticoagulation therapy (ACT) in patients with high-risk atrial fibrillation (AF) in terms of reduction in vascular events, including stroke. The existing guidelines acknowledge an increased risk of bleeding associated with such a strategy; however, there is no consensus on the treatment pathway.

U2 - 10.3310/hta17300

DO - 10.3310/hta17300

M3 - Article

C2 - 23880057

VL - 17

SP - 1

EP - 188

JO - Health Technology Assessment

JF - Health Technology Assessment

SN - 1366-5278

IS - 30

ER -